Syngene International Limited’s Post

High titers and shorter timelines are essential for efficient protein production. Enhancing gene expression consistency during the cell line development stage is a crucial strategy to overcome this challenge.   Check out our latest feature on BioPharma Dive, where we explore the key bottlenecks in gene expression and share effective solutions to streamline processes and improve reliability.   Read the full article 👉 https://lnkd.in/gxuY9dEf   #Biologics #ProteinProduction #GeneExpression #CellLineDevelopment #Syngene #Biopharma #ResearchInnovation #SynWeave

ATUM takes you from concept to bench in as little as 5 days. Meet your research deadlines with the industry’s fastest, most reliable gene synthesis. Nobody does it better than ATUM. Discover how ATUM can move you forward: https://hubs.li/Q02L8GwL0 #GeneDesign #GeneSynthesis #biologics

𝗪𝗵𝘆 𝗱𝗼 𝗴𝗲𝗻𝗲 𝗲𝗱𝗶𝘁𝗶𝗻𝗴 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀 𝗿𝗲𝗾𝘂𝗶𝗿𝗲 𝗿𝗲𝗱𝗲𝗳𝗶𝗻𝗲𝗱 𝗮𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝗮𝗹 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀❓ In the newest #vodcast episode, Hugo Gagnon from Allumiqs takes a deep dive into what gene editing is and uncovers why establishing analytics for gene editing is such a complex task. Watch now to get inspired to #RewriteTheRules of your laboratory 👇 https://bit.ly/3VaTpWH #biopharma #Biopharmaceutical #podcast #video #GeneEditing

Thoughts on this? >> Gene therapies start the climb from rare disease base camps to common disease peaks - Nature.com >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #competitivemarketing #pharmaceutical #healthcare

Thoughts on this? >> Gene therapies start the climb from rare disease base camps to common disease peaks - Nature.com >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #competitivemarketing #pharma #healthcare

Biotechnology revolutionizes healthcare, agriculture, and industry through genetic engineering, gene therapy, bioremediation, and pharmaceutical innovation, shaping a dynamic future. #Genetic #engineeringmaterials #biopharmaceuticals #bioremediation #Bioinformatics #LISA𓃠 #Neech

The interesting thing about the CYP2D6 allele is that it's highly multigenic. There are many identified gene variants with gene deletions, duplications, and paired inheritance being possible. Pharmacogenomics, like any science, is evolving, and sometimes there is some inherent ambiguity to the results. Using myself as an example. When I got my results back, the lab listed SIX probable results for my CYP2D6 phenotype. One of my alleles was definitive and coded for "no function"; the other was one of two structurally similar alleles, both coding for "normal function". The lab also determined that one of my alleles was duplicated, but which of two was uncertain. A duplicate "no function" allele doesn't create a "less than 0" functioning allele; 0+0 is still 0. However, a duplicate "normal function" allele DOES create a "greater than 1" functioning allele. Functional phenotype is determined by adding the scores of each allele. "Ultrarapid Metabolizer" is a score of >2.25, "Normal Metabolizer" is a "1.25-2.25", "Intermediate Metabolizer" is a 0.25-1, and "Poor Metabolizer" is a 0. With my alleles being classified a "1 or 2" and a "0", I am potentially a "Normal Metabolizer" OR an "Intermediate Metabolizer". This DOES make a difference in whether certain drugs will/will not work for me. This is where a clinician needs to weigh all available information and make an educated recommendation. Because I have already had several poor responses to medications, I am fairly confident that the "no function" allele is the duplication and that my true phenotype is "Intermediate Metabolizer". While I don't like uncertainty, coming across it in my OWN test results has given me some excellent questions to research ahead of seeing my first patients. #Pharmacogenomics #CompleteMedicationManagement #PatientCare

Dreaming of an easy method of buffer exchange and concentration for your biologic or gene therapy samples? See how Big Tuna makes your dreams come true by flying through sample prep of up to 96 samples per run in less than 15 minutes of hands-on time so you're free to work or play while Big Tuna takes on all the heavy lifting. Learn more here: https://lnkd.in/gxDTFV2    #biologics #genetherapy  

Thoughts on this? >> Intellia’s gene editing therapy succeeds in Phase 2 genetic swelling condition study >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharma #productmarketing #pharmaceutical

Thoughts on this? >> Intellia’s gene editing therapy succeeds in Phase 2 genetic swelling condition study >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #biotech #productmarketing #pharma